• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/19/21 11:44:25 AM ET
    $HJLI
    Medical/Dental Instruments
    Health Care
    Get the next $HJLI alert in real time by email
    SC 13G 1 tm217209d5_sc13g.htm SCHEDULE 13G

     

    CUSIP No: 41015N304

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. ____)*

     

    Hancock Jaffe Laboratories, Inc.
    (Name of Issuer)

     

    Common Stock, $0.00001 par value per share

    (Title of Class of Securities)

     

    41015N304
    (CUSIP Number)

     

    February 9, 2021

    (Date of Event Which Requires Filing of this statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No: 41015N304

     

    (1) NAMES OF REPORTING PERSONS
     
        CVI Investments, Inc.
     
      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
        (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
      (3) SEC USE ONLY
     
      (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
        Cayman Islands
         
    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0  
     
    BENEFICIALLY (6) SHARED VOTING POWER **
     
      435,714
    OWNED BY
     
    EACH (7) SOLE DISPOSITIVE POWER
     
    REPORTING 0
     
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
     
      435,714
       
      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
        435,714
       
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        5.6%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
         
        CO

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 41015N304

     

    (1) NAMES OF REPORTING PERSONS
     
        Heights Capital Management, Inc.
         
      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
        (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
      (3) SEC USE ONLY
         
      (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
        Delaware
         

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0  
     
    BENEFICIALLY (6) SHARED VOTING POWER **
     
    OWNED BY 435,714
       
         
    EACH (7) SOLE DISPOSITIVE POWER
     
    REPORTING 0  
     
     
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
     
      435,714
       

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
        435,714
     
     
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        5.6%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
         
        CO

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 41015N304

     

    Item 1.

     

    (a)Name of Issuer

     

      Hancock Jaffe Laboratories, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

      70 Doppler, Irvine, California 92618

     

    Item 2(a). Name of Person Filing

     

      This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.00001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Common stock, $0.00001 par value per share

     

    Item 2(e) CUSIP Number

     

    41015N304

     

     

     

     

    CUSIP No: 41015N304

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
     
    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
     
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
     
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
    (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The Company’s Prospectus (Registration Nos. 333-251528 and 333-252874), filed on February 10, 2021, indicates there were 7,732,208 Shares outstanding (excluding Shares underlying warrants issued at the same time) as of the completion of the offering of the Shares referred to therein.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

     

     

     

    CUSIP No: 41015N304

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 41015N304

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 19, 2021

     

    CVI INVESTMENTS, INC. HEIGHTS CAPITAL MANAGEMENT, INC.
       
    By: Heights Capital Management, Inc. By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Name: Brian Sopinsky
    Attorney, a copy of which is attached as Exhibit I hereto Title: Secretary

     

    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

     

     

     

    CUSIP No: 41015N304

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney
    II   Joint Filing Agreement

     

     

     

     

    CUSIP No: 41015N304

     

    Exhibit I

     

    LIMITED POWER OF ATTORNEY

     

    THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. (hereinafter called "the Company"), whose Registered Office is situated at PO Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands.

     

    WHEREAS, by agreement dated July 16, 2015, by and between the Company and Heights Capital Management, Inc., the Company expressly authorized Heights Capital Management, Inc. to enter into transactions in certain designated areas as defined in the Discretionary Investment Management Agreement attached hereto marked "Appendix l."

     

    NOW THIS DEED WITNESSETH that William Walmsley, Director of the Company, hereby appoints on behalf of the Company the firm of HEIGHTS CAPITAL MANAGEMENT, INC., which through its officers, directors and employees is hereby formally granted limited power of attorney for the purpose of entering into transactions on behalf and for the account of the Company; and to take all actions on behalf of the Company as may be necessary to consummate such transactions, including but not limited to making, negotiating; signing, endorsing, executing, acknowledging and delivering in the name of the Company all applications, contracts, agreements, notes, statements, certificates, proxies and any other instruments of whatever kind and nature as may be necessary or proper in connection with the entering into of such transactions, instructing the transfer of funds where necessary with respect to such transactions, and performing all of the services specified under the Discretionary Investment Management Agreement with respect to such transactions.

     

    IN WITNESS WHEREOF, the Company has caused this Limited Power of Attorney to take effect on the day and year above written.

     

      CVI Investments, Inc.
       
      By:  /s/ William Walmsley
        William Walmsley, Director

     

     

     

     

    CUSIP No: 41015N304

     

    EXHIBIT II

     

    JOINT FILING AGREEMENT

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of common stock of Hancock Jaffe Laboratories, Inc., $0.00001 par value per share, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

     

    Dated as of February 19, 2021

     

    CVI INVESTMENTS, INC. HEIGHTS CAPITAL MANAGEMENT, INC.
       
    By: Heights Capital Management, Inc. By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Attorney Name: Brian Sopinsky
    Title: Secretary
    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

     

    Get the next $HJLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HJLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HJLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • enVVeno Medical Corporation Successfully Completes Rebranding

      Company Now Trading Under Ticker Symbol "NVNO"IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully completed its rebranding and that its shares are now trading under the ticker symbol "NVNO" on The Nasdaq Capital Market. The Company was formerly called Hancock Jaffe Laboratories, Inc.For shareholders of the Company holding shares in electronic form, the name change will require no action. Shareholders with physical stock certificates should contact the Company's transfer agent to obtain new certificates.For more i

      10/1/21 7:02:00 AM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

      Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe LaboratoriesIRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, today announced that Robert Berman, CEO of Hancock Jaffe will participate in The Duologue Series hosted by Ladenburg Thalmann on Monday, September 27, 2021 at 1:00 PM ET.The webinar will be moderated by Jeffrey S. Cohen, Managing Director of Ladenburg Thalmann. Following the discussion, there will be a question and answer se

      9/24/21 9:00:00 AM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

      - Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -- Development strategy to focus on venous disease and advancement of the VenoValve® -- Initiated development of second product for the treatment of venous disease; expected to be unveiled in mid-2022 -- Management to host a conference call with live video webcast at 4:30 p.m. ET today, September 21st -IRVINE, CA / ACCESSWIRE / September 21, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, announced today a corporate update which

      9/21/21 4:00:00 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care

    $HJLI
    Financials

    Live finance-specific insights

    See more

    $HJLI
    SEC Filings

    See more
    • Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

      - Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -- Development strategy to focus on venous disease and advancement of the VenoValve® -- Initiated development of second product for the treatment of venous disease; expected to be unveiled in mid-2022 -- Management to host a conference call with live video webcast at 4:30 p.m. ET today, September 21st -IRVINE, CA / ACCESSWIRE / September 21, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, announced today a corporate update which

      9/21/21 4:00:00 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

      Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ETIRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Hancock Jaffe management will host a corporate update conference call with a live video webcast on Tuesday, September 21, 2021 at 4:30 p.m. ET.As part of the call, management will discuss VenoValve's continued development and other ongoing corporate initiatives. The call will be led by Robert Berman, Chief Executive Officer of Hancock Jaffe, who will be joined by Dr. Marc Glickman

      9/15/21 8:05:00 AM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • Hancock Jaffe Laboratories, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - enVVeno Medical Corp (0001661053) (Filer)

      10/1/21 5:29:00 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • Hancock Jaffe Laboratories, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)

      9/22/21 8:15:22 AM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Hancock Jaffe Laboratories, Inc.

      8-K - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)

      9/8/21 4:49:36 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care

    $HJLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Hancock Jaffe Laboratories, Inc.

      SC 13G - Hancock Jaffe Laboratories, Inc. (0001661053) (Subject)

      9/17/21 5:08:01 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Hancock Jaffe Laboratories, Inc. (0001661053) (Subject)

      2/19/21 11:44:25 AM ET
      $HJLI
      Medical/Dental Instruments
      Health Care

    $HJLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Gray Robert converted options into 1,042 units of Common Stock, increasing direct ownership by 19% to 6,614 units

      4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)

      9/15/21 9:50:12 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Jenusaitis Matthew converted options into 1,042 units of Common Stock, increasing direct ownership by 22% to 5,884 units

      4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)

      9/15/21 9:50:17 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Jenusaitis Matthew bought $10,010 worth of Common Stock (1,300 units at $7.70), increasing direct ownership by 37% to 4,842 units

      4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)

      8/27/21 3:19:33 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care